

1 **The Effect of Diabetes and Prediabetes on Anti-tuberculosis Treatment Outcomes:**
2 **A Multicentric Prospective Cohort Study**

3 **Authors:** María B. Arriaga^{1,2,3*}, Mariana Araújo-Pereira^{1,2,3*}, Beatriz Barreto-Duarte^{1,2,4*},
4 Betânia Nogueira^{2,3,5*}, Maria Vitória C.N.S. Freire⁶, Artur T.L. Queiroz^{2,7}, Moreno M.S.
5 Rodrigues⁸, Michael S. Rocha^{2,5}, Alexandra B. Souza^{9,10}, Renata Spener-Gomes^{9,10,11},
6 Anna Cristina C. Carvalho^{12,13}, Marina C. Figueiredo¹⁴, Megan M. Turner¹⁴, Betina
7 Durovni¹⁵, José R. Lapa-e-Silva¹², Afrânio L. Kritski¹², Solange Cavalcante¹⁵, Valeria C.
8 Rolla¹⁶, Marcelo Cordeiro-Santos^{9,10,17}, Timothy R. Sterling¹⁴, Bruno B. Andrade^{1,2,3,4,6,14}
9 for the RePORT Brazil consortium[#].

10

11 **#RePORT Brazil consortium (in addition to those listed above as main authors):** Alice
12 M. S. Andrade^{1,2}, Vanessa Nascimento^{2,5}, Hayna Malta-Santos^{1,3}, Jéssica Rebouças-
13 Silva^{1,3}, Alysson G. Costa^{9,10}, Jaqueline Silva⁹, Jamile G. de Oliveira¹⁵, Aline Benjamin¹⁶,
14 Adriano Gomes-Silva¹⁶, Flavia M. Sant'Anna¹⁶, Francine P. Ignácio¹⁶, Maria Cristina
15 Lourenço¹⁸, Elisangela C. Silva¹², Adriana S. R. Moreira¹², Mayla Mello¹

16

17

18 ¹Laboratório de Inflamação e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz,
19 Salvador, Brazil

20 ²Multinational Organization Network Sponsoring Translational and Epidemiological Research
21 (MONSTER) Initiative, Salvador, Brazil

22 ³Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil

23 ⁴Curso de Medicina, Universidade Salvador (UNIFACS), Salvador, Brazil

24 ⁵Instituto Brasileiro para Investigação da Tuberculose, Fundação José Silveira, Salvador, Brazil

25 ⁶Curso de Medicina, Escola Bahiana de Medicina e Saúde Pública (EBMSP), Salvador, Brazil

26 ⁷Center of Data and Knowledge Integration for Health (CIDACS), Instituto Gonçalo Moniz,
27 Fundação Oswaldo Cruz, Salvador, Brazil

28 ⁸Laboratório de Análise e Visualização de Dados, Fundação Oswaldo Cruz, Porto Velho, Brazil

29 ⁹Fundação Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil

30 ¹⁰Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas,
31 Manaus, Brazil

32 ¹¹ Universidade Federal do Amazonas, Manaus, Brazil

33 ¹²Programa Acadêmico de Tuberculose da Faculdade de Medicina, Universidade Federal do Rio
34 de Janeiro, Rio de Janeiro, Brazil

35 ¹³Laboratório de Inovações em Terapias, Ensino e Bioprodutos (LITEB), Instituto Oswaldo Cruz,
36 Fiocruz, Rio de Janeiro, Brazil

37 ¹⁴Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of
38 Medicine, Nashville, Tennessee, USA

39 ¹⁵Secretaria Municipal de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil

40 ¹⁶Laboratório de Pesquisa Clínica em Micobacteriose, Instituto Nacional de Infectologia Evandro
41 Chagas, Fiocruz, Rio de Janeiro, Brazil

42 ¹⁷Universidade Nilton Lins, Manaus, Brazil

43 ¹⁸Bacteriology and Bioassay Laboratory, National Institute of Infectious Diseases Evandro Chagas,
44 Oswaldo Cruz Foundation, Rio de Janeiro, Brazil

45

46

47 ^{*}MBA, MA-P, BB-D and BN equally contributed to the work.

48 **Correspondence:** Bruno B. Andrade, MD, PhD, Laboratório de Inflamação e
49 Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Rua Waldemar

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

50 Falcão, 121, Candeal, Salvador, Bahia 40296-710, Brazil. Phone: +55-71-3176-2264 E-
51 mail: bruno.andrade@fiocruz.br

52 **Keywords:** Diabetes; Prediabetes; treatment outcome; SINAN; *Mycobacterium*
53 *tuberculosis*.

54 **Running Head:** Dysglycemia impacts TB treatment outcomes

55 **40-word summary of the article's main point:** In a multicenter prospective cohort study from
56 Brazil, diabetes was associated with an increased risk of unfavorable treatment outcomes,
57 including mortality, in pulmonary tuberculosis patients. These observations were validated in
58 the Brazilian National Disease Notification System during the same period.

59 **Abstract word count:** 200

60 **Main MS text word count:** 2895

61 **Figures:** 04

62 **Tables:** 02

63 **Supplementary Figure:** 02

64 **Supplementary Tables:** 04

65 **ABSTRACT**

66 **Background:** It is unclear whether diabetes or prediabetes drives adverse treatment
67 outcomes and death in people with tuberculosis (PWTB).

68 **Methods:** Culture-confirmed PWTB, enrolled in the Regional Prospective Observational
69 Research in Tuberculosis (RePORT)-Brazil cohort between 2015 and 2019 (n=756) were
70 stratified based on glycemic status by baseline glycosylated hemoglobin levels. Unfavorable
71 TB outcome was defined as treatment failure or modification, recurrence or death,
72 whereas favorable outcome was cure or treatment completion. We validated the findings
73 using data from PWTB reported to the Brazilian National System of Diseases Notification
74 (SINAN) during 2015-2019 (n=20,989). Stepwise binary multivariable regression analysis
75 models evaluated associations between glycemic status and unfavorable outcomes.

76 **Results:** In both cohorts, in univariate analysis, unfavorable outcomes were more
77 frequently associated with drug resistance and HIV infection. Diabetes was associated
78 with unfavorable outcomes in the RePORT (aOR: 2.85, p=0.001) and in SINAN (aOR:
79 1.56, p=0.040) cohorts. Furthermore, diabetes was associated with higher risk of death in
80 both, RePORT-Brazil (aOR:3.23, p=0.006) and in the SINAN (aOR:2.75, p= 0.047)
81 cohorts.

82 **Conclusion:** Diabetes was associated with an increased risk of unfavorable outcomes
83 and mortality in Brazilian PWTB. Interventions to improve tuberculosis treatment
84 outcomes in persons with diabetes are needed.

85 INTRODUCTION

86 Diabetes (DM) is recognized by the World Health Organization (WHO) as a global
87 epidemic [1]. This metabolic disease triples the risk of active tuberculosis (TB) in
88 patients with latent *Mycobacterium tuberculosis* (Mtb) infection [2]. In 2019,
89 approximately 400,000 people with tuberculosis (PWTB) worldwide were also
90 diagnosed with diabetes [3] . Importantly, DM prevalence is increasing globally,
91 including settings with a high (TB) burden, such as China and India [4].

92 The high prevalence of DM among TB patients (10% - 30%) in high TB burden
93 countries and the negative impact of TB-DM comorbidity has been previously
94 described by many groups [5-8] such as: higher mycobacterial loads and
95 prevalence of sputum AFB positive, failure and death outcomes TB treatment,
96 among others.

97 We have reported an association between DM and more severe TB clinical
98 presentation (higher frequency of cough, night sweats, hemoptysis and malaise)
99 [9], increased lung pathology reflected by severe radiographic manifestations
100 (higher number of pulmonary lesions, including cavitation) [10], increased bacterial
101 load in sputum [11] and delayed sputum conversion after anti-tuberculosis
102 treatment initiation [12]. Furthermore, activation of tissue remodeling responses
103 [12] and increased and persistent systemic inflammation [13] have been reported
104 during treatment in TBDM patients. Thus, the increase in the number of people
105 with DM may further complicate care and control of TB, especially in many areas
106 with a high burden of both diseases [14].

107 There is also evidence that patients with concomitant TB and DM have an
108 increased risk of unfavorable anti-tuberculosis treatment outcome such as failure,

109 recurrence and death compared to normoglycemic patients [15-17]. However, the
110 findings have not been consistent [18, 19]. In the present study we evaluated the
111 effect of dysglycemia (DM or pre-DM) on anti-tuberculosis treatment outcomes in
112 a prospective Brazilian cohort of patients with pulmonary TB (Regional Prospective
113 Observational Research in Tuberculosis (RePORT)-Brazil), and also among
114 PWTB reported to the Brazilian National TB Registry through the National System
115 of Diseases Notification (SINAN).

116

117 **MATERIALS AND METHODS**

118 **Ethics Statement**

119 The study was conducted according to the principles in the Declaration of Helsinki.
120 The RePORT-Brazil protocol was approved by the institutional review boards at
121 each study site and at Vanderbilt University Medical Center. The protocol, informed
122 consent, and study documents were approved by the institutional review boards at
123 all study sites. The Institutional Review Boards and the protocol approval numbers
124 are as follows: (i) Instituto de Pesquisa Clínica Evandro Chagas, Fundação
125 Oswaldo Cruz, Rio de Janeiro, Brazil (protocol no. 688.067), (ii) Secretaria
126 Municipal de Saude do Rio de Janeiro, Brazil (protocol no. 740.554), (iii) Hospital
127 Universitario Clementino Fraga Filho Rio de Janeiro, Brazil (protocol no. 852.519),
128 (iv) Maternidade Climério de Oliveira, Universidade Federal da Bahia, Salvador,
129 Brazil (protocol no. 723.168), (v) Fundação de Medicina Tropical Dr. Heitor Vieira
130 Dourado, Manaus, Brazil (protocol no. 807.595). Participation was voluntary and
131 written informed consent was obtained from all participants. Participation in
132 RePORT-Brazil was voluntary, and written informed consent was obtained from all

133 participants. All data extracted from SINAN were public and freely accessible. The
134 anonymity of study subjects was preserved; all data were de-identified.

135 **Overall Study Design**

136 RePORT-Brazil includes five study sites, located in cities with high TB burden:
137 Salvador, Manaus, and Rio de Janeiro [20]. One main objective of the consortium
138 is to describe the clinical outcomes of TB treatment and latent *Mtb* infection in
139 Brazil. The details of the sites and representativeness of the RePORT-Brazil cohort
140 to all TB patients in Brazil have been described previously [20].

141 For the current analysis, we included RePORT-Brazil participants with pulmonary
142 TB \geq 18 years old enrolled between June 2015 and June 2019 (**Figure1A**), with
143 new or previously diagnosed culture-positive sputum (Lowenstein-Jensen medium
144 or BD BACTEC MGIT), who received anti-tuberculosis treatment and had a
145 treatment outcome recorded in the study database. Clinical and epidemiological
146 information was collected at three in-person visits (i) anti-TB treatment initiation
147 (baseline), (ii) two months after initiating treatment, and (iii) at the completion of
148 anti-TB treatment. In addition, telephone follow-up was performed for all
149 participants every 6 months until up to month 24 (when it corresponded). All data
150 collected was stored in REDCap [21].

151 To establish the glycemic status of PWTB, baseline HbA1c in blood was measured.
152 DM was defined according to American Diabetes Association (ADA) guidelines
153 [22]. Patients were classified as having DM (HbA1c \geq 6.5%), pre-diabetes (pre-DM;
154 HbA1c=5.7%-6.4%) or normoglycemia (HbA1c $<$ 5.7%). HbA1c \geq 5.7% was
155 classified as dysglycemia.

156 SINAN is the Brazilian National System of Notification of Diseases [23], and
157 includes diseases that require notification in all states and municipalities of Brazil;
158 TB is a notifiable disease. The details of SINAN have been previously described
159 [20]. PWTB reported to SINAN are diagnosed following the criteria in the Brazilian
160 Manual of Recommendations for Tuberculosis control [24]. Diagnostic criteria
161 include: (i) clinical and epidemiologic factors (presumptive diagnosis), (ii)
162 bacteriology (sputum smear positive) or positive culture for Mtb (solid or liquid
163 media), (iii) positive Xpert MTB RIF, (iv) chest radiography or (v) in the case of
164 extrapulmonary TB, histopathology [24]. For each TB case reported,
165 characteristics such as sex, age, race, education, alcohol consumption, illicit drug
166 use, smoking habits, comorbidities, presence of HIV infection and test results,
167 among others were also reported. Glycemic status was reported to SINAN as a
168 diagnosis of diabetes (yes / no), not exclusively based on HbA1c level.

169 We used the SINAN information from the years 2015 to 2019 to match the
170 enrollment period of RePORT-Brazil (see ref. [20] and **Figure 1B**). Of note, in 2014
171 the “Strategies for Care of people with Chronic diseases”, addressing
172 comprehensive basic care for patients with TB and DM among others [25], was
173 implemented in Brazil. In addition, we used the sub-set of data reported from
174 Salvador, Manaus, and Rio de Janeiro, the cities with RePORT Brazil study sites.

175

176 **Outcome definition**

177 The primary outcome in this study was an unfavorable treatment outcome defined
178 as treatment modification, treatment failure, recurrence, or death (during
179 treatment). The secondary outcome was mortality (death for any reason during

180 treatment). All definitions of outcome treatments were established in accordance
181 with the Manual of Recommendations for the Control of TB of Brazil [24]. The
182 treatment outcome definitions used in RePORT-Brazil and SINAN are depicted in
183 **Supplementary Table 1**. A favorable outcome was defined as cure or treatment
184 completion (defined as at least 90% of the total number of doses over one year for
185 drug-susceptible TB and two years for TB-MDR). Patients who were lost to follow-
186 up or transferred out or had a change in diagnosis (not a TB case) as the treatment
187 outcome were excluded. The numbers of participants per outcome in this study are
188 shown in more detail in **Figure 1A and 1B**.

189

190 **Data analysis**

191 All analyses were pre-specified. Median and interquartile ranges (IQR) were used
192 as measures of central tendency. Categorical variables were represented as
193 percentages and compared using a two-sided Pearson's chi-square test with Yates
194 correction or the Fisher's two-tailed test in 2x3 or 2x2 tables, respectively.
195 Quantitative variables were compared using the Mann Whitney *U* test. We
196 performed a logistic binary regression with backward stepwise selection in both
197 the RePORT-Brazil and SINAN cohorts using variables with univariate p -value \leq
198 0.2 to identify independent associations between characteristics of TB patients
199 (one model for each stratification strategy of the glycemc status: dysglycemia,
200 diabetes, prediabetes, and HbA1c value) with the composite unfavorable treatment
201 outcome or with mortality alone. Results from both regression approaches were
202 presented in terms of point estimates and 95% confidence intervals (CI). P -values
203 < 0.05 were considered statistically significant. Statistical analyses were performed

204 using SPSS 25.0 (IBM statistics), Graphpad Prism 9.0 (GraphPad Software, San
205 Diego, CA) and JMP 13.0 (SAS, Cary, NC, USA).

206 RESULTS

207 Factors associated with tuberculosis treatment outcomes in RePORT-Brazil

208 The RePORT cohort included 756 participants had culture-confirmed pulmonary
209 TB who were treated with anti-tuberculosis drugs for at least 6 months. Patients
210 were grouped according to treatment outcomes: favorable (n=654, 86.5%) and
211 unfavorable (n=102, 13.5%) (**Figure 1A**). The median age in RePORT cohort was
212 36 years [interquartile range (IQR): 25-49]. Most study participants were male in
213 both groups. Patients with unfavorable outcomes more frequently reported current
214 smoking (p=0.03), alcohol consumption (p=0.01) and illicit drug use (p=0.001)
215 (**Table 1**). These patients also had higher frequency of resistance to isoniazid
216 (p=0.006) or rifampicin (p=0.002), multi-drug resistance (p=0.009), diabetes
217 (p=0.003) and HIV infection (p<0.001) (**Table 1**). The proportion of individuals with
218 dysglycemia (i.e., with diabetes or prediabetes) did not differ significantly between
219 those with unfavorable vs. favorable outcomes. In contrast, persons with
220 unfavorable outcomes had lower hemoglobin levels (10.6 g/dL (IQR:8.98-12.4) vs.
221 12.2 g/dL (IQR:10.9-13.4) among those with favorable outcomes, p<0.001 (**Table**
222 **1**). In addition, no differences were found in the proportion of individuals with
223 dysglycemia among those with drug-susceptible vs. multidrug resistant TB
224 (**Supplementary Table 2**).

225 Regarding TB clinical presentation at study enrollment, patients who developed
226 unfavorable outcomes more often were living with HIV (p<0.001) and presented
227 with fatigue (p<0.001), whereas those who experienced a favorable treatment
228 outcome more frequently presented with cough (p<0.001) and hemoptysis
229 (p=0.043). (**Supplementary Figure 1A and B**).

230 We next evaluated the impact of baseline glycemic status on treatment outcomes.
231 Dysglycemia was more frequent in TB patients who failed therapy ($p=0.03$) or died
232 ($p=0.043$) during TB treatment (**Figure 2**). Baseline Hb1Ac values were
233 distinguishable between the subgroups of participants who further developed
234 favorable and unfavorable outcome when the outcomes were examined
235 individually (treatment modification, failure, death, recurrence, and cure).
236 Individuals with favorable treatment outcomes had lower HbA1c levels than those
237 who experienced treatment modification ($p=0.042$), failure ($p=0.024$), and death
238 ($p=0.048$) during treatment follow up. Among individuals with unfavorable
239 outcomes, those who experienced treatment modification had lower Hb1Ac values
240 than patients who had treatment failure ($p=0.004$) or died ($p=0.016$) (**Figure 2**).
241 Furthermore, TB patients who experienced failure, recurrence or died exhibited a
242 median HbA1c of 6g/dL (IQR:5.4-6.8).

243

244 **Determinants of TB treatment outcomes in Brazilian National System of** 245 **Notification of Diseases**

246 In the SINAN cohort, with data also collected from 2015 to 2019, 20,989 PWTB
247 were notified in the three cities where RePORT study sites are located. Males
248 represented more than 60% of patients in both groups, and patients with
249 unfavorable outcomes were older (45 years, IQR:32-58, $p<0.001$), more frequently
250 reported smoking ($p<0.001$), alcohol consumption ($p<0.001$), illicit drugs use
251 ($p<0.001$), and were less likely to report antiretroviral treatment (ART) ($p=0.009$)
252 than those with favorable outcome. Unfavorable outcome was associated with
253 previous TB ($p<0.001$), positive culture ($p<0.001$), diabetes ($p=0.015$), HIV co-

254 infection ($p < 0.001$), and other comorbidities ($p < 0.001$) (**Table 2, Supplementary**
255 **Figure 1C**).

256 Furthermore, we likewise evaluated the impact of glycemic status on the TB clinical
257 presentation by the study participants in both cohorts (**Supplementary Figure 2**).

258 In RePORT patients, weight loss was more commonly observed in PWDM than in
259 those with prediabetes or normoglycemia ($p < 0.001$). In patients from SINAN, there
260 was a higher proportion of PWTB with dysglycemia presenting with a positive
261 smear at baseline than in those with normoglycemia ($p < 0.001$). In addition,
262 frequency of HIV infection was higher in the normoglycemic patients from the
263 SINAN dataset ($p < 0.001$). More details of other clinical factors are displayed in
264 the **Supplementary Figure 2**.

265

266 **Multivariable logistic regression to assess association between glycemic** 267 **status and tuberculosis treatment outcomes**

268 A binomial logistic regression analysis was performed to test independent
269 associations between the status of glycemia (dysglycemia, DM, pre-DM or HbA1c
270 values) and treatment outcome in the RePORT cohort. DM was associated with
271 unfavorable treatment outcomes independent of the other factors (adjusted OR
272 [aOR]: 2.85, 95% CI: 1.57-5.17, $p = 0.001$) (**Figure 3, Model 2**). This analysis also
273 was performed in SINAN cohort and DM was independently associated with
274 unfavorable TB treatment outcomes (aOR: 1.56, 95% CI: 1.04-2.52, $p = 0.04$)
275 (**Figure 3**).

276 **Mortality during tuberculosis treatment**

277 We next compared patients with favorable outcome versus those who died during
278 TB treatment (n=55). Mortality was associated with male sex (p=0.039), increasing
279 age (p=0.002), *pardo* race (61.8%, p=0.028), smoking (p=0.011) and illicit drug
280 use (p=0.019), resistance to isoniazid (p=0.02), to rifampicin (p=0.004), multidrug
281 resistance (p=0.049), HIV infection (p<0.001), diabetes (p=0.005) and with lower
282 concentrations of hemoglobin (death: 9.45 g/dL, IQR:7.95-10.99; cure:12.2,
283 IQR:11-13.4, p<0.001) and higher values of HbA1c (death:6.2%, IQR:5.2-7.1;
284 cure: 5.7%, IQR: 5.4-6.2, p < 0.001) (**Supplementary Table 3**).

285 In the SINAN cohort, the subgroup of “death” as outcome showed the same
286 statistically significant variables than those detected when we compared the
287 composite unfavorable outcome *versus* cure (**Supplementary Table 4**). Patients
288 who were successfully treated were younger (p<0.001), less likely to report
289 smoking (p<0.001), alcohol consumption (p<0.002), illicit drug use (p<0.018), HIV
290 infection (p<0.001) and other comorbidities (p=0.009) in comparison to those who
291 died during TB treatment in both cohorts. In SINAN, patients who developed a
292 favorable outcome had a lower frequency of diabetes (p=0.011) and higher
293 frequency of ART use (p=0.001).

294 A logistic regression analysis was performed comparing cure and death and
295 presented similar results to the first model exploring the composite unfavorable
296 outcome. In the RePORT cohort, DM was once again strongly associated with
297 mortality (aOR: 3.23, 95%CI: 1.39-7.43, p=0.006) (**Figure 4, Model 2**). In the
298 SINAN cohort, DM was also significantly associated with death (aOR: 2.75, 95%CI:
299 1.02-7.42, p=0.047) (**Figure 4**).

300 **DISCUSSION**

301 There has recently been increased recognition of DM as an important risk factor
302 for developing active TB and experiencing unfavorable TB treatment outcomes.
303 [14-16, 26] As the prevalence of DM increases [27], particularly in developing
304 countries, it is necessary to determine the public health impact of this syndemic in
305 large populations. Our study analyzed data from PWTB in two data sources, a
306 longitudinal cohort, and the nationwide disease notification system in the same
307 period and the same three cities to determine the impact of DM on TB treatment
308 outcomes in a Brazilian population.

309 It is interesting to note the factors that were consistently associated with poor
310 outcomes in the two datasets analyzed, namely substance use (alcohol, tobacco,
311 and illicit drug) and HIV infection, all in accordance with previous literature [19, 28]
312 but different from other studies [29]. The analyses from RePORT also identified
313 other drug resistance, anemia and normal chest radiograph as factors associated
314 with worse outcomes. This latter observation may be due to the fact that RePORT
315 performs systematic collection of these variables, which coincides with findings
316 from other studies [19, 30].

317 In addition to the above factors, we found an association between higher HbA1c
318 levels and treatment modification, treatment failure and death, when compared
319 with the HbA1c levels among TB patients who were successfully treated, and this
320 was reflected in the significantly higher proportion of PWD among those with
321 unfavorable anti-tuberculosis treatment outcomes. In the RePORT cohort, the
322 odds of having an adverse outcome was 2.85 times higher in DM patients
323 compared to normoglycemic individuals. An odds ratio of 1.56 was found in the
324 SINAN dataset. The relative lower detection of DM cases in SINAN dataset

325 probably led to underestimation of the effect of DM in TB outcomes found in the
326 analysis. Our results are similar to those from previous studies [13, 16]. The odds
327 of death in the DM groups were 3.23 times higher than in normoglycemic patients
328 in RePORT dataset and 2.5 in SINAN dataset. The odds ratio of death in the
329 RePORT cohort was more compatible with what has been described in literature
330 [16]. Previous studies showed how TBDM comorbidity is associated with a higher
331 burden of immune pathology and systemic inflammation compared to TB
332 normoglycemic patients [13, 31]. Furthermore, a defective regulation of the innate
333 immune response in TBDM patients could maintain inflammatory foci despite anti-
334 tuberculosis treatment, resulting in worse treatment results [13].

335 Moreover, all participants from RePORT had HbA1c measured at baseline visit,
336 whereas in SINAN the diagnosis of DM was self-reported in most cases, possibly
337 missing many diagnoses. Of note, a longitudinal cohort study done in Brazil found
338 that 50% of individuals diagnosed with DM did not know about their diagnosis [32].
339 Thus, in the SINAN cohort, with increasing clinical evidence that diabetes is a risk
340 factor for developing active TB [2] and that worsens the clinical TB presentation
341 [9], screening for diabetes was increased over the recent years. But the problem
342 of under-diagnosis and sub-notification still exists.

343 The findings presented here suggest that the impact of DM in TB in Brazil is
344 underestimated. While the results reiterate the value of cohorts like RePORT in
345 better delineating the local epidemiology, it highlights the importance of guidelines
346 recommending laboratory investigation of DM in all TB incident cases and to
347 establish specific treatment recommendations for this population. This implies
348 long-term glycemetic control that is essential to improve the outcome of TB treatment
349 in patients with TBDM comorbidity [33]. The integrated care of individuals with both

350 diseases has specific challenges such as the interaction between oral antidiabetic
351 and anti-tuberculosis drugs [34] and the greater risk for adverse events [35].

352 We did not find an association between unfavorable outcome and death with pre-
353 DM/dysglycemia in the RePORT cohort, but only with DM. Previous studies
354 reported the normalization of glycemic levels during the treatment of TB, persons
355 who were dysglycemic prior to anti-TB treatment [36, 37]. Therefore, the
356 deleterious effects on the immune response caused by chronic DM hyperglycemia
357 would not be observed in pre-DM, which could explain the lack of association with
358 unfavorable and death outcomes [36, 37] .

359 This study had several limitations. First, both RePORT and SINAN are
360 observational cohorts; unmeasured or residual confounding could have explained
361 the findings. Second, SINAN is a disease notification system that is not part of a
362 study protocol. While SINAN represents TB cases from all of Brazil, there could be
363 incomplete data collection or endpoint ascertainment, as well as different sources
364 of information (i.e., self-reported *versus* information from medical charts) for
365 different patients. Third, we did not have information on serum drug levels; low
366 drug levels have been associated with unfavorable TB treatment outcomes,
367 including in TB patients with advanced HIV and DM [38]. Nevertheless, we believe
368 it brings valuable information on the impact of TB-DM on a population level.

369 Diabetes is a disease with growing prevalence and a major risk factor for
370 unfavorable outcomes, including death during treatment, in individuals with TB,
371 along with HIV infection and substance use. Actions prioritizing these groups are
372 essential for the control of TB in Brazil.

373 **NOTES**

374 **Acknowledgments:** The authors thank the study participants. We also thank the
375 teams of clinical and laboratory platforms of RePORT Brazil. A special thanks to
376 Elze Leite (FIOCRUZ, Salvador, Brazil), Eduardo Gama (FIOCRUZ, Rio de
377 Janeiro, Brazil), Elcimar Junior (FMT-HVD, Manaus, Brazil), Hilary Vansell
378 (VUMC, Nashville, USA) and Letícia C.M. Linhares (VUMC, Nashville, USA) for
379 administrative and logistical support.

380 **Funding:** The study was supported by the Intramural Research Program of the
381 Fundação Oswaldo Cruz, Intramural Research Program of the Fundação José
382 Silveira, Departamento de Ciência e Tecnologia (DECIT) - Secretaria de Ciência
383 e Tecnologia (SCTIE) – Ministério da Saúde (MS), Brazil [25029.000507/2013-07]
384 and the National Institutes of Allergy and Infectious Diseases [U01-AI069923].
385 M.B.A. received a fellowship from the Fundação de Amparo à Pesquisa da Bahia
386 (FAPESB). M.A.-P. received a fellowship from Coordenação de Aperfeiçoamento
387 de Pessoal de Nível Superior (Finance code: 001). B.B.A., J.R.L.S. and A.K. are
388 senior investigators of the Conselho Nacional de Desenvolvimento Científico e
389 Tecnológico (CNPq), Brazil.

390 **Disclaimer:** The funder of the study had no role in the study design, data
391 collection, or data analysis; however, a representative of the Brazilian Ministry of
392 Health (A.K.) was involved in data interpretation and writing the report.

393 **Conflicts of interest:** All authors: No reported conflicts of interest.

394 **Author contributions:** Conceptualization, T.R.S., M.C.F., M.C.S., V.C.R., and
395 B.B.A.; Data curation, M.B.A., M.A-P., .A.T.L.Q., M.M.S.R., and B.B.A.;
396 Investigation, M.B.A., B.B.-D., M.A-P., B.N., A.B.S., M.S.R., A.B., RS-G., M.C.F.,

397 B.D., J.R.L.S., A.L.K., S.C., V.C.R., T.R.S., M.C.S., and B.B.A.; Formal analysis,
398 M.B.A., M.A-P., A.T.L.Q., M.M.S.R. and B.B.A.; Funding acquisition, B.D.,
399 J.R.L.S., A.L.K., S.C., V.C.R., T.R.S., M.C.S., M.C.F., and B.B.A.; Methodology,
400 M.B.A., B.B.-D., M.A-P and B.B.A.; Project administration, M.C.F., T.R.S., and
401 B.B.A.; Resources, M.B.A., G.A., T.R.S., and B.B.A.; Software, M.B.A., M.A-P.,
402 A.T.L.Q., M.M.S.R., M.C.F., T.R.S., and B.B.A.; Supervision, T.R.S., and B.B.A.;
403 Writing—original draft, M.B.A., B.B-D., M.A-P., B.N., M.V.C.N.S.F. and B.B.A.;
404 Writing—review and editing, all authors. All authors have read and agreed to the
405 submitted version of the manuscript.

406 REFERENCES

- 407
- 408 1. World Health Organization. Global Report on Diabetes., **2016**.
 - 409 2. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis:
410 a systematic review of 13 observational studies. *PLoS Med* **2008**; 5(7): e152.
 - 411 3. World Health Organization. Global Tuberculosis Report 2020, **2020**.
 - 412 4. World Health Organization. Collaborative framework for care and control of
413 tuberculosis and diabetes, **2011**.
 - 414 5. Cheng J, Zhang H, Zhao YL, Wang LX, Chen MT. Mutual Impact of Diabetes
415 Mellitus and Tuberculosis in China. *Biomed Environ Sci* **2017**; 30(5): 384-9.
 - 416 6. Kreisel CF, Passannante MR, Lardizabal AA. The Negative Clinical Impact of
417 Diabetes on Tuberculosis: A Cross-Sectional Study in New Jersey. *J Endocr Soc*
418 **2019**; 3(1): 62-8.
 - 419 7. Kumar Nathella P, Babu S. Influence of diabetes mellitus on immunity to human
420 tuberculosis. *Immunology* **2017**; 152(1): 13-24.
 - 421 8. Sembiah S, Nagar V, Gour D, Pal DK, Mitra A, Burman J. Diabetes in
422 tuberculosis patients: An emerging public health concern and the determinants
423 and impact on treatment outcome. *J Family Community Med* **2020**; 27(2): 91-6.
 - 424 9. Gil-Santana L, Almeida-Junior JL, Oliveira CA, et al. Diabetes Is Associated with
425 Worse Clinical Presentation in Tuberculosis Patients from Brazil: A Retrospective
426 Cohort Study. *PLoS One* **2016**; 11(1): e0146876.
 - 427 10. Barreda NN, Arriaga MB, Aliaga JG, et al. Severe pulmonary radiological
428 manifestations are associated with a distinct biochemical profile in blood of
429 tuberculosis patients with dysglycemia. *BMC Infect Dis* **2020**; 20(1): 139.
 - 430 11. Almeida-Junior JL, Gil-Santana L, Oliveira CA, et al. Glucose Metabolism
431 Disorder Is Associated with Pulmonary Tuberculosis in Individuals with
432 Respiratory Symptoms from Brazil. *PLoS One* **2016**; 11(4): e0153590.
 - 433 12. Mesquita ED, Gil-Santana L, Ramalho D, et al. Associations between systemic
434 inflammation, mycobacterial loads in sputum and radiological improvement after
435 treatment initiation in pulmonary TB patients from Brazil: a prospective cohort
436 study. *BMC Infect Dis* **2016**; 16: 368.
 - 437 13. Kumar NP, Fukutani KF, Shruthi BS, et al. Persistent inflammation during anti-
438 tuberculosis treatment with diabetes comorbidity. *Elife* **2019**; 8.
 - 439 14. Restrepo BI. Diabetes and Tuberculosis. *Microbiol Spectr* **2016**; 4(6).
 - 440 15. Dousa KM, Hamad A, Albirair M, et al. Impact of Diabetes Mellitus on the
441 Presentation and Response to Treatment of Adults With Pulmonary Tuberculosis
442 in Qatar. *Open Forum Infect Dis* **2019**; 6(1): ofy335.
 - 443 16. Huangfu P, Ugarte-Gil C, Golub J, Pearson F, Critchley J. The effects of diabetes
444 on tuberculosis treatment outcomes: an updated systematic review and meta-
445 analysis. *Int J Tuberc Lung Dis* **2019**; 23(7): 783-96.
 - 446 17. Yoon YS, Jung JW, Jeon EJ, et al. The effect of diabetes control status on
447 treatment response in pulmonary tuberculosis: a prospective study. *Thorax* **2017**;
448 72(3): 263-70.
 - 449 18. Kornfeld H, Sahukar SB, Procter-Gray E, et al. Impact of Diabetes and Low Body
450 Mass Index on Tuberculosis Treatment Outcomes. *Clin Infect Dis* **2020**; 71(9):
451 e392-e8.
 - 452 19. Chaves Torres NM, Quijano Rodriguez JJ, Porras Andrade PS, Arriaga MB,
453 Netto EM. Factors predictive of the success of tuberculosis treatment: A
454 systematic review with meta-analysis. *PLoS One* **2019**; 14(12): e0226507.
 - 455 20. Arriaga MB, Amorim G, Queiroz ATL, et al. Novel Stepwise Approach to Assess
456 Representativeness of a Large Multicenter Observational Cohort of Tuberculosis
457 Patients: The Example of RePORT Brazil. *Int J Infect Dis* **2020**.
 - 458 21. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
459 electronic data capture (REDCap)--a metadata-driven methodology and workflow

- 460 process for providing translational research informatics support. *J Biomed Inform*
461 **2009**; 42(2): 377-81.
- 462 22. American Diabetes Association. Glycemic targets: Standards of Medical Care in
463 Diabetes. *Diabetes Care* **2020**; 42(Supplement 1): S187-S93.
- 464 23. Ministério da Saúde do Brasil, Secretaria de Vigilância em Saúde. Sistema de
465 Informação de Agravos de Notificação. Available at:
466 <http://portalsinan.saude.gov.br/>. Accessed 08-14-2020).
- 467 24. Ministério da Saúde do Brasil, Secretaria de Vigilância em Saúde. Manual de
468 Recomendações para o Controle da Tuberculose no Brasil. **2013**:288.
- 469 25. Estratégias para o cuidado da pessoa com doença crônica. Brazil: Cadernos de
470 Atenção Básica, **2014**:146.
- 471 26. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of
472 two epidemics. *Lancet Infect Dis* **2009**; 9(12): 737-46.
- 473 27. International Diabetes Federation. *Diabetes Atlas*. 9 ed, **2019**.
- 474 28. Myers B, Bouton TC, Ragan EJ, et al. Impact of alcohol consumption on
475 tuberculosis treatment outcomes: a prospective longitudinal cohort study
476 protocol. *BMC Infect Dis* **2018**; 18(1): 488.
- 477 29. Wang Q, Ma A, Han X, et al. Prevalence of type 2 diabetes among newly
478 detected pulmonary tuberculosis patients in China: a community based cohort
479 study. *PLoS One* **2013**; 8(12): e82660.
- 480 30. Calderon RI, Arriaga MB, Lopez K, et al. High prevalence and heterogeneity of
481 Dysglycemia in patients with tuberculosis from Peru: a prospective cohort study.
482 *BMC Infect Dis* **2019**; 19(1): 799.
- 483 31. Prada-Medina CA, Fukutani KF, Pavan Kumar N, et al. Systems Immunology of
484 Diabetes-Tuberculosis Comorbidity Reveals Signatures of Disease
485 Complications. *Sci Rep* **2017**; 7(1): 1999.
- 486 32. Schmidt MI, Hoffmann JF, de Fatima Sander Diniz M, et al. High prevalence of
487 diabetes and intermediate hyperglycemia - The Brazilian Longitudinal Study of
488 Adult Health (ELSA-Brasil). *Diabetol Metab Syndr* **2014**; 6: 123.
- 489 33. Critchley JA, Restrepo BI, Ronacher K, et al. Defining a Research Agenda to
490 Address the Converging Epidemics of Tuberculosis and Diabetes: Part 1:
491 Epidemiology and Clinical Management. *Chest* **2017**; 152(1): 165-73.
- 492 34. Arbex MA, Varella Mde C, Siqueira HR, Mello FA. Antituberculosis drugs: drug
493 interactions, adverse effects, and use in special situations. Part 1: first-line drugs.
494 *J Bras Pneumol* **2010**; 36(5): 626-40.
- 495 35. Siddiqui AN, Khayyam KU, Sharma M. Effect of Diabetes Mellitus on
496 Tuberculosis Treatment Outcome and Adverse Reactions in Patients Receiving
497 Directly Observed Treatment Strategy in India: A Prospective Study. *Biomed Res*
498 *Int* **2016**; 2016: 7273935.
- 499 36. Boillat-Blanco N, Ramaiya KL, Mganga M, et al. Transient Hyperglycemia in
500 Patients With Tuberculosis in Tanzania: Implications for Diabetes Screening
501 Algorithms. *J Infect Dis* **2016**; 213(7): 1163-72.
- 502 37. Magee MJ, Salindri AD, Kyaw NTT, Auld SC, Haw JS, Umpierrez GE. Stress
503 Hyperglycemia in Patients with Tuberculosis Disease: Epidemiology and Clinical
504 Implications. *Curr Diab Rep* **2018**; 18(9): 71.
- 505 38. Park JS, Lee JY, Lee YJ, et al. Serum Levels of Antituberculosis Drugs and Their
506 Effect on Tuberculosis Treatment Outcome. *Antimicrob Agents Chemother* **2016**;
507 60(1): 92-8.

508

509 **TABLES**

510 **Table 1. Characteristics of persons with TB in the RePORT-Brazil cohort by treatment**
511 **outcomes**

Characteristics	Unfavorable (n=102)	Favorable (n=654)	p-value
Male, n (%)	71 (69.6)	415 (63.5)	0.267
Age, median (IQR)	38 (27-52)	36 (25-49)	0.208
Race, n (%)			0.050
White	18 (17.6)	147 (22.5)	
Black	22 (21.6)	168 (25.7)	
Asian	0 (0)	4 (0.6)	
Pardo	57 (55.9)	325 (49.8)	
Indigenous	5 (4.9)	9 (1.4)	
Illiterate, n (%)	97 (95.1)	626 (95.7)	0.793
Smoking, n (%)^a	66 (64.7)	317 (48.5)	0.030
Alcohol consumption, n (%)^b	94 (92.2)	537 (82.1)	0.010
Illicit drug use, n (%)^c	44 (43.1)	176 (26.9)	0.001
Prior TB, n (%)	17 (16.8)	110 (16.9)	1
Type of TB, n (%)^d			0.235
PTB	87 (85.3)	585 (89.4)	
PTB+EPTB	15 (14.7)	69 (10.6)	
Abnormal X-ray, n (%)	95 (93.1)	639 (97.7)	0.020
Positive smear, n (%)	81 (79.4)	528 (80.7)	0.788
Resistance, n (%)			
Isoniazid	13 (13.1)	33 (5.2)	0.006
Rifampicin	8 (8.1)	11 (1.7)	0.002
Any drug ^e	11 (11.1)	71 (11.1)	1
Multidrug ^f	6 (6.1)	9 (1.4)	0.009
DOT, n (%)	53 (51.9)	368 (56.3)	0.543
Glycemic status, n (%)			
Diabetes	37 (36.3)	128 (19.6)	0.003
Prediabetes	25 (24.5)	230 (35.2)	0.43
Normoglycemia	40 (39.2)	296 (45.3)	Ref.
Dysglycemia, n (%)	62 (60.8)	358 (54.7)	0.284
Metformin use, n (%)^g	2 (5.4)	9 (7.0)	0.516
Hemoglobin (g/dL), median (IQR)	10.6 (8.98-12.4)	12.2 (10.95-13.4)	<0.001
HbA1c (%), median (IQR)	6 (5.4-6.8)	5.7 (5.4-6.2)	0.054
HIV status, n (%)	45 (44.6)	100 (15.5)	<0.001
ART, n (%)^h	13 (28.9)	34 (33.7)	0.702
Hypertension, n (%)	11 (10.8)	56 (8.6)	0.455
Other comorbidities, n (%)ⁱ	13 (12.7)	32 (4.9)	<0.001

512 **Table Note:** Data represent n. (%) or median with Interquartile range (IQR).

513 Favorable: cure/complete treatment. Unfavorable: failure, recurrence, treatment modification or
514 death.

515 In RePORT-Brazil all patients had a positive culture at baseline.

516 ^aSmoking: Past or current cigarette smoker. ^bAlcohol consumption: Past or current any
517 consumption of alcohol. ^cIllicit drug use: Past or current illicit drug use (marijuana, cocaine, heroin

518 or crack). ^dAll individuals from the RePORT cohort had a diagnosis of pulmonary tuberculosis, in
519 some cases with presence in other anatomical sites. ^eAny drug (anti-tuberculosis) resistance
520 except rifampicin and isoniazid: Pyrazinamide, ethambutol, streptomycin, kanamycin,
521 ethionamide. ^fMultidrug: TB caused by Mycobacterium Tuberculosis (*M. tuberculosis*) strains that
522 are resistant to at least both rifampicin and isoniazid. Only patients with the diabetes condition
523 used metformin. ^gThe frequency of use of metformin was calculated only in patients with diabetes.
524 ^hART frequency was calculated among the persons living with HIV. ⁱ It include cancer, kidney
525 disease, chronic obstructive pulmonary disease, emphysema, and asthma.
526 Abbreviations: TB: Tuberculosis. PTB: Pulmonary TB. EPTB: Extrapulmonary TB. HIV: Human
527 Immunodeficiency Virus. DOT: Directly Observed Therapy. ART: Antiretroviral therapy.

528 **Table 2. Characteristics of people with TB in the SINAN (2015-2019) cohort by**
529 **outcomes**

Characteristics	Unfavorable (n=260)	Favorable (n=23747)	p-value
Male, n (%)	177 (68.1)	13010 (62.8)	0.082
Age, median (IQR)	39 (32-49)	38 (28-52)	0.217
Race, n (%)			0.674
White	64 (26.7)	5116 (26.4)	
Black	56 (23.3)	3495 (18.1)	
Asian	4 (1.7)	170 (0.9)	
Pardo	116 (48.3)	10500 (54.3)	
Indigenous	0 (0)	62 (0.3)	
Illiterate, n (%)	35 (19.1)	2422 (15.3)	0.147
Smoking, n (%)^a	68 (30)	3540 (18)	<0.001
Alcohol consumption, n (%)^b	53 (23.3)	2600 (13.1)	<0.001
Illicit drug use, n (%)^c	40 (17.8)	1873 (9.6)	<0.001
Prior TB, n (%)	101 (38.8)	3209 (15.5)	<0.001
Type of TB, n (%)^d			0.107
PTB	247 (95)	20071 (96.8)	
EPTB	4 (1.5)	117 (0.6)	
PTB+EPTB	9 (3.5)	541 (2.6)	
Abnormal X-ray, n (%)	220 (97.8)	17914 (97.3)	1
Positive smear, n (%)	157 (80.9)	10718 (76.3)	0.150
Positive culture, n (%)	116 (85.9)	5877 (71.2)	<0.001
Resistance, n (%)			<0.001
Isoniazid	34 (13.7)	76 (0.3)	<0.001
Rifampicin	7 (2.7)	9 (0.03)	<0.001
Any drug ^e	40 (15.4)	145 (55.8)	<0.001
Multidrug ^f	12 (4.6)	13 (0.05)	<0.001
DOT, n (%)	112 (64.7)	10107 (60.6)	0.275
Diabetes, n (%)	36 (15.4)	2066 (10.4)	0.015
HIV infection, n (%)	46 (21.3)	1906 (10.6)	<0.001
ART, n (%)^g	23 (50)	1225 (64.3)	0.009
Hypertension, n (%)	5 (1.9)	567 (2.7)	0.564
Other comorbidities, n (%)^h	23 (9.1)	804 (4.0)	<0.001

530 **Table Note:** Data represent n. (%) or median with Interquartile range (IQR).

531 Favorable: cure/complete treatment. Unfavorable: failure, recurrence, treatment modification
532 or death.

533 ^aSmoking habits: Past or current cigarette smoker. ^bAlcohol consumption: Past or current any
534 consumption of alcohol. ^cIllicit drug use: Past or current illicit drug use (marijuana, cocaine, heroin
535 or crack). ^dOnly individuals from the SINAN 2015-2019 cohort that had a diagnosis of pulmonary
536 tuberculosis, in some cases with presence in other anatomical sites, were included. ^eAny drug
537 (anti-tuberculosis) resistance except rifampicin and isoniazid: Pyrazinamide, ethambutol,
538 streptomycin, kanamycin, ethionamide. ^fMultidrug: TB caused by *Mycobacterium Tuberculosis*
539 strains that are resistant to at least both rifampicin and isoniazid. ^gART frequency was calculated
540 among the persons living with HIV. ^h It include cancer, kidney disease, chronic obstructive
541 pulmonary disease, emphysema, and asthma.

542 Abbreviations: TB: Tuberculosis. PTB: Pulmonary TB. EPTB: Extrapulmonary TB. HIV:
543 Human Immunodeficiency Virus. DOT: Directly Observed Therapy. ART: Antiretroviral
544 therapy.
545
546

547 FIGURES AND LEGENDS

548 **Figure 1: Study flowchart.**

549 Flowchart presenting the PWTB included and excluded from **(A)** RePORT-Brazil and PWTB
550 reported to **(B)** SINAN between 2015- 2019.

551 Abbreviations: RePORT: Regional Prospective Observational Research for Tuberculosis.

552 SINAN: Sistema de Informação de Agravos de Notificação. TB: Tuberculosis.

553

554

555 **Figure 2. Distribution of the glycemic status and Hb1Ac levels according to treatment** 556 **outcomes in TB patients in RePORT-Brazil.**

557 Frequency of PWTB with diabetes, prediabetes, normoglycemia and dysglycemia (diabetes +
558 prediabetes) diagnosed using HbA1c levels is shown according to the TB treatment outcomes

559 (cure, treatment modification, failure, death, and recurrence). Only comparisons (frequency

560 dysglycemia status between TB treatment outcomes) with significant p-values are displayed.

561 Scatter plots depicting the frequency of HbA1c values in TB patients according to TB treatment

562 outcome. Lines represent median and interquartile range values. The differences in median values

563 HbA1c between groups were compared using the Kruskal-Wallis test with Dunn's multiple

564 comparisons post-test. Only comparisons with significant p-values are displayed.

565 Abbreviations: HbA1c: glycated hemoglobin, normoglyc.: normoglycemia

566

567

568 **Figure 3. Association between glycemic status and TB treatment outcomes among TB** 569 **patients from RePORT-Brazil and SINAN cohorts.**

570 In Report-Brazil cohort (upper panel) logistic regression models (backward stepwise regression)
571 were performed to evaluate the independent associations between glycemic status of tuberculosis

572 patients (Model 1: dysglycemia, Model 2: diabetes, Model 3: prediabetes and Model 4: increases

573 of 1 unit in HbA1c level) and variables with p-value < 0.2 results in the univariate analyses (**Table**

574 **1**) and unfavorable treatment outcome (treatment modification, failure, recurrence, and death).

575 In SINAN cohort (lower panel) logistic regression models (backward stepwise regression) were

576 performed to evaluate the independent associations between diabetes of tuberculosis and

577 variables with p-value<0.2 results in the univariate analyses (**Table 2**) and unfavorable treatment

578 outcome (treatment modification, failure, and death).

579 Abbreviations: RePORT: Regional Prospective Observational Research for Tuberculosis. SINAN:

580 Sistema de Informação de Agravos de Notificação. TB: Tuberculosis. MDR-TB: multidrug-resistant

581 tuberculosis. IDU: illicit drug use. PTB: pulmonary tuberculosis. HbA1c: glycated hemoglobin.

582

583

584 **Figure 4. Association between glycemic status and death during anti-tuberculosis** 585 **treatment among TB patients from RePORT-Brazil and SINAN cohorts.**

586 In Report-Brazil cohort (upper panel) logistic regression models (backward stepwise regression)
587 were performed to evaluate the independent associations between glycemic status of tuberculosis

588 patients (Model 1: dysglycemia, Model 2: diabetes, Model 3: prediabetes and Model 4: increases

589 of 1 unit in HbA1c level) and variables with p-value < 0.2 results in the univariate analyses

590 (**Supplementary Table 3**) and death.

591 In SINAN cohort (lower panel) logistic regression models (backward stepwise regression) were

592 performed to evaluate the independent associations between diabetes of tuberculosis patients in

593 the period 2015-2019 and variables with p-value<0.2 results in the univariate analyses

594 (**Supplementary Table 4**) and death.

595 Abbreviations: RePORT: Regional Prospective Observational Research for Tuberculosis. SINAN:

596 Sistema de Informação de Agravos de Notificação (Brazilian National System of Notification of

597 Diseases) TB: Tuberculosis. HbA1c: glycated hemoglobin.

598

A**RePORT-Brazil
(n=1187)****431 excluded**

- 129 loss to follow-up
- 13 transferred out
- 267 ongoing in treatment
- 22 *Non-Mycobacterium tuberculosis*

654 favorable outcome

- 421 cure
- 233 treatment complet

102 unfavorable outcome

- 13 treatment modification
- 27 failure
- 53 death
- 9 recurrence

B**SINAN (2015-2019)
(n=23273)****2284 excluded**


- 1678 loss to follow-up
- 449 transferred out
- 157 *Non-Mycobacterium tuberculosis*

20729 favorable outcome

- 20729 cure

260 unfavorable outcome

- 140 treatment modification
- 9 failure
- 111 death



		Glycemic Status	TB Treatment outcome	Model		Odds ratio (95%CI)	p-value
RePORT-Brazil	Model 1	Dysglycemia	Favorable Unfavorable (%) 0 20 40 60 80	unadjusted adjusted		1.28 (0.84-1.96) 1.43 (0.86-2.34)	0.284 0.163
	Model 2	Diabetes	Favorable Unfavorable (%) 0 10 20 30 40	unadjusted adjusted		2.14 (1.31-3.50) 2.85 (1.57-5.17)	0.003 0.001
	Model 3	Prediabetes	Favorable Unfavorable (%) 0 10 20 30 40	unadjusted adjusted		0.80 (0.47-1.37) 0.81 (0.43-1.52)	0.430 0.523
	Model 4	HbA1c	<ul style="list-style-type: none"> ● Favorable ● Unfavorable HbA1c (%) 0 6 10 14 18	unadjusted adjusted		1.04 (0.94-1.14) 1.10 (0.99-1.21)	0.054 0.060
SINAN	2015-2019	Diabetes	Favorable Unfavorable (%) 0 5 10 15 20	unadjusted adjusted		1.57 (1.10-2.24) 1.56 (1.04-2.52)	0.015 0.040
					0 1 2 3 4 associated with unfavorable outcome		

